Delivering enhanced cardiovascular disease and hypertension care through private health facilities in Pakistan

Delivering enhanced cardiovascular disease and hypertension care through private health facilities in Pakistan: a cluster randomized trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN34381594

Enrollment

912

Registered

2012-07-26

Start date

2012-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension / Cardiovascular Disease Circulatory System Atherosclerotic cardiovascular disease

Interventions

Intervention arm Quality care will be delivered to adult hypertension patients, through enabled private healthcare facilities. The inputs for delivering quality care will include: 1. Operational gui

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. All newly diagnosed hypertensive (systolic blood pressure >140 mm Hg, diastolic blood pressure >90 mm Hg) 2. Male and female patients aged 25 years or more from the catchment population of the respective facility

Exclusion criteria

Exclusion criteria: 1. Pregnant women 2. Persons with advanced chronic disease 3. Person with conditions that cause secondary hypertension 4. Person with known history of hypertension and/or CVD treatment in the past 5. Person not likely to stay in the area for the required follow-up period of 15 months

Design outcomes

Primary

Measure	Time frame
Measure the comparison is hypertension control. This outcome measure will be taken at the completion of 15 months of patient registration. The hypertension control at 15 months will be measured in terms of mean change in systolic blood pressure, i.e. change of mean blood pressure compared to the baseline. The blood pressure measurements at the registration and at completion of 15 months will be taken and recorded by an external expert assessor, not involved in trial implementation and also kept blind to the trial arms (with a mercury apparatus).	—

Measure

Time frame

Measure the comparison is hypertension control. This outcome measure will be taken at the completion of 15 months of patient registration. The hypertension control at 15 months will be measured in terms of mean change in systolic blood pressure, i.e. change of mean blood pressure compared to the baseline. The blood pressure measurements at the registration and at completion of 15 months will be taken and recorded by an external expert assessor, not involved in trial implementation and also kept blind to the trial arms (with a mercury apparatus).

—

Secondary

Measure	Time frame
1. Glycaemic control 2. Cholesterol control and tobacco cessation among the registered hypertension patients The glycaemic control and cholesterol control at 15 months will be measured in terms of mean change in HbA1c and change in serum cholesterol respectively. A recognized quality assured laboratory service will be used for HbA1c and serum cholesterol testing at the baseline and 15 months follow-up. In addition to these three key outcome measures, an additional set of process, output and outcome measures will also be selected, through TWG process, for comparing the intervention and control.	—

Measure

Time frame

1. Glycaemic control 2. Cholesterol control and tobacco cessation among the registered hypertension patients The glycaemic control and cholesterol control at 15 months will be measured in terms of mean change in HbA1c and change in serum cholesterol respectively. A recognized quality assured laboratory service will be used for HbA1c and serum cholesterol testing at the baseline and 15 months follow-up. In addition to these three key outcome measures, an additional set of process, output and outcome measures will also be selected, through TWG process, for comparing the intervention and control.

—

Countries

Pakistan

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 22, 2026